Anti-silencing function 1B knockdown suppresses the malignant phenotype of colorectal cancer by inactivating the phosphatidylinositol 3-kinase/AKT pathway

Table 1 Association between clinical parameters of colorectal cancer patients and anti-silencing function 1B expression

Variable	Total	ASF1B expression (n = 68)		P value
		Low (n = 34)	High (n = 34)
Age				0.622
< 45 yr	28 (3.69 ± 0.74)	15 (3.11 ± 0.33)	13 (4.41 ± 0.37)
45 yr	40 (3.73 ± 0.62)	19 (3.20 ± 0.39)	21 (4.21 ± 0.37)
Gender				0.4667
Female	33 (3.68 ± 0.68)	18 (3.16 ± 0.35)	15 (4.30 ± 0.41)
Male	35 (3.74 ± 0.66)	16 (3.17 ± 0.39)	19 (4.24 ± 0.37)
Tumor size				0.4921
< 2 cm	24 (3.77 ± 0.71)	11 (3.14 ± 0.42)	13 (4.31 ± 0.36)
≥ 2 cm	44 (3.68 ± 0.65)	24 (3.20 ± 0.35)	20 (4.26 ± 0.40)
TNM stage				0.0035b
I/II	41 (3.54 ± 0.64)	27 (3.16 ± 0.38)	14 (4.26 ± 0.35)
III/IV	27 (3.99 ± 0.62)	8 (3.25 ± 0.35)	19 (4.30 ± 0.40)
Lymph node metastasis				0.0158a
Negative	36 (3.32 ± 0.68)	29 (2.97 ± 0.35)	7 (4.21 ± 0.42)
Positive	32 (3.95 ± 0.55)	17 (3.40 ± 0.24)	15 (4.30 ± 0.37)
Distant metastasis				0.0040b
Negative	30 (3.39 ± 0.64)	20 (3.02 ± 0.33)	10 (4.12 ± 0.43)
Positive	38 (3.98 ± 0.57)	12 (3.31 ± 0.28)	26 (4.28 ± 0.38)

^aP < 0.05.

^bP < 0.01.

TNM: Tumor node metastasis; ASF1B: Anti-silencing function 1B.